Sor102 Jun 2026

Current biologic therapies typically target a single pathway, such as or IL-23 . While effective, many patients experience a loss of response over time. SOR102 changes the game by combining two humanized single-domain antibodies into one molecule: Anti-TNF

SOR102: A Breakthrough in Oral Biologics for Ulcerative Colitis sor102

Localized activity confirmed by minimal systemic drug levels in the blood. Why it Matters: Breaking the "Therapeutic Ceiling" sor102

Could you clarify which of these you mean? sor102

Greater decreases in the and rectal bleeding.